期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

NMP22在膀胱癌诊断中的研究进展 被引量：3

Progress of NMP22 in Diagnosis for Bladder Cancer
下载PDF
导出
摘要 在国内外,膀胱癌的发病率在男、女性泌尿生殖系统肿瘤中均居于前列,且近几年有年轻化及上升之势。寻找早期诊断膀胱癌的无创性、简便而有高敏感度、高特异度的新肿瘤标志物有着重要的临床意义。文章对膀胱癌特异性核基质蛋白22的研究现状、进展进行了探讨,提出尿液中核基质蛋白22检测在膀胱癌早期诊断和治疗及判定预后有着重大的潜在价值。
作者 朴永锋 刘鹏 朴春南
机构地区 浙江省肿瘤医院 吉林大学中日联谊医院
出处 《肿瘤学杂志》 CAS 2008年第2期154-156,共3页 Journal of Chinese Oncology
关键词 膀胱肿瘤 核基质蛋白 诊断 尿 肿瘤标志物
分类号 R737.14 [医药卫生—肿瘤]
  • 相关文献

参考文献24

  • 1Soloway MS, Briggman JV, Carpinito GA, et al. Use of a new tumor maker, urinary NMP22, in the deteetion of occult or rapidly reeurring transitional cell carcinoma of the urinary tract following surgical treatment[J]. J Urol, 1996, 156(2 Pt 1):363-367.
  • 2Lyderson BK, Pettojohn DE. Human-specific nuclear protein that associates with the polar region of the mitotic apparatus: distribution in a human/hamster hybrid cell [J]. Cell, 1980, 22(2 Pt 2):489-499.
  • 3Yang CH,Lambie EJ, Snyder M. NuMA: an unusually long coiled-coil related protein in the mammalian nucleus[J]. J Cell Biol, 1992, 116(6):1303-1317.
  • 4Keesee K, Briggman JV, Thill G, et al. Utilization of nuclear matrix proteins for cancer diagnosis[J]. Crit Rev Eukaryot Gene Expr, 1996, 6(2-3):189-214.
  • 5Hughes JH, Cohen MB. Nuclear matrix proteins and their potential applications to diagnostic pathology[J]. Am J Clin Pathol, 1999, 111(2):267-274.
  • 6Sanchez-Carbayo M, Herrero E, Megias J, et al. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer [J]. J Urol, 1999, 162(6):1957-1958.
  • 7Zippe C, Pandrangi L, A garwal A. NMP22 is sensitive, cost-effective test in patients at risk for bladder cancer [J]. J Urol, 1999, 161(1):62-65.
  • 8Sanchez-Carbayo M, Herrero E, Megias J, et al. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder [J]. BJU Int, 1999, 84(6):706-713.
  • 9Sozen S, Biri H, Sinik Z, et al. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA star test in the diagnosis of transitional cell carcinoma of the bladder[J]. Eur Urol, 1999, 36(3):225-229.
  • 10魏学斌,李青,赵庆利,门同义,李博,徐祗顺.尿NMP_(22)检测诊断膀胱癌的价值[J].山东医药,2005,45(9):12-13. 被引量：1

二级参考文献35

  • 1[1]Sharma S, Zippe CD, Pandrangi L, et al. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat [J]. J Urol,1999,162(1):53-57.
  • 2[2]Malmstrom PU, Busch C, Norlen BJ, et al. Recurrence, progression and survival in bladder cancer: A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up [J]. Scand J Urol Nephrol, 1987, 21:185-195.
  • 3[3]Stampfer DS, Carpinito GA, Rodriguezvillanueva J, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder [J]. J Urol, 1998,159:394-398.
  • 4[4]Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer [J]. J Urol, 1999, 161:62-65.
  • 5[5]Carpinito GA, Stadler WM, Briggman JV, et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract [J]. J Urol, 1996,156:1280-1285.
  • 6[6]Miyanaga N, Akaza H, Ishikawa S, et al. Clinical evaluation of nuclear matrix protein 22(NMP22)in urine as a novel marker for urothelial cancer [J]. Eur Urol, 1997,31:163-168.
  • 7[7]Sanchez-Carbayo M, Herreo E, Megias J, et al. Comparative sensitivity of urinary CYFRA21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer [J]. J Urol, 1999,162:1951-1956.
  • 8[8]Soloway MS, Briggman V, Carpinito GA, et al. Use of a new tumor marker,urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment [J]. J Urol, 1996,156(2ptal):363-367.
  • 9[9]Casella R, Lehmann K, Gasser TC. Re: NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer [J]. J Urol, 1999,162:500-501.
  • 10[1]Lee K H.Evaluation of the NMP22 test and comparision with voided urine cytology in the detection of bladder cancer[J].Yonsel Med J, 2001, 42(1):14-18.

共引文献10

同被引文献24

  • 1何朝宏,肖传国,杜茂信.尿核基质蛋白22在膀胱癌术后复发监测中的应用[J].临床泌尿外科杂志,2005,20(2):107-108. 被引量：3
  • 2马利民,张跃平,张芹,周树军,王惠民.尿核基质蛋白检测在膀胱癌诊断中的应用价值评定[J].临床泌尿外科杂志,2005,20(3):175-177. 被引量：4
  • 3苏大军,宋力.尿核基质蛋白22在膀胱移行细胞癌诊断及术后复发监测中的应用[J].第四军医大学学报,2007,28(8):706-708. 被引量：2
  • 4Droller M J. Evaluation of the clinical value of urinary NMP22 as a maker for screening and surveillance of transitional cell carcinoma of the urinary bladder [J]. J Urol, 2002, 168(2) :857-858.
  • 5Keesee S K, Briggman J V, Thill C, et al. Utilization of nuclear matrix proteins for cancer diagnosis[J]. Crit Rev Eukaryot Gene Expr, 1996,6(2):189-214.
  • 6Carpinito G A, Stadler W M, Briggman J V, et al. Urinary nuclear matrix proteinas a marker for transitional cell carcinoma of the urinary tract[J]. J Urol, 1996, 156(4) : 1280-1285.
  • 7Sanchez-carbayo M, Urrutia M, Silva J M, et al. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA21 - 1 and NMP22 for evaluating sympotomatic patients at risk for bladder cancer[J]. J Urol, 2001,165 (5):1462-1467.
  • 8Kibar Y, Goktas S, Kilic S, etal. Prognostic value of cytology, nuclear matrix protein 22(NMP22) test, and urinary bladder cancer Ⅱ (UBC Ⅱ) test in early recurrent transitional cell carcinoma of the bladder[J]. Ann Clin Lab Sci. 2006,36(1):31-38.
  • 9Soloway M S, Briggman J V, Carpinito G A, et al. Use of a new tumor marker,Urinary NMP22 ,in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment[J]. J Urol, 1996, 159:363-367.
  • 10KAUFMAN D S, SHIPLEY W U, FELDMAN A S. Bladder cancer[J]. Lancet, 2009, 374 (9685) : 239 - 249.

引证文献3

二级引证文献3

肿瘤学杂志
2008年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部